Donor-derived posttransplant lymphoproliferative disease detection by donor-derived cell-free DNA
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Donor-derived cell-free DNA (dd-cfDNA) detected elevated levels in a kidney transplant patient, signaling early posttransplant lymphoproliferative disorder (PTLD). This finding enabled prompt treatment, leading to complete remission and preserved kidney function.
Area Of Science
- Transplantation immunology
- Oncology
- Molecular diagnostics
Background
- Posttransplant lymphoproliferative disorder (PTLD) is a serious complication following organ transplantation.
- Diagnosis often relies on nonspecific symptoms or transplant organ dysfunction.
- Routine surveillance typically focuses on allograft rejection.
Observation
- A kidney transplant recipient exhibited significantly elevated donor-derived cell-free DNA (dd-cfDNA) during routine surveillance.
- Initial presentation lacked organ dysfunction or biopsy-confirmed rejection.
- Subsequent imaging revealed lymphadenopathy and an allograft mass, diagnosed as PTLD/diffuse large B cell lymphoma.
Findings
- Elevated dd-cfDNA levels preceded clinical and biopsy-proven PTLD diagnosis.
- Next-generation sequencing confirmed the lymphoma was donor-derived.
- The patient achieved complete remission with retained kidney function after treatment.
Implications
- Circulating dd-cfDNA may serve as an early detection marker for donor-derived malignancies like PTLD.
- Monitoring dd-cfDNA could enable earlier intervention in rare post-transplant complications.
- This approach may improve outcomes for transplant recipients with donor-derived cancers.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.